Research progress of immunotherapy in esophageal squamous cell carcinoma
10.3760/cma.j.cn371439-20200708-00082
- VernacularTitle:食管鳞状细胞癌免疫治疗进展
- Author:
Wenqian YANG
1
;
Junxing HUANG
Author Information
1. 南通大学临床医学系 226000
- Keywords:
Esophageal neoplasms;
Immunotherapy;
T-lymphocytes, cytotoxic;
Programmed death-1;
Immune checkpoint inhibitor
- From:
Journal of International Oncology
2021;48(7):429-432
- CountryChina
- Language:Chinese
-
Abstract:
With the development of immunotherapy in clinical application, immunotherapy also takes advantage in esophageal squamous cell carcinoma (ESCC). Immune checkpoint inhibitors such as programmed death-1 (PD-1) and its ligand PD-L1 and cytotoxic T lymphocyte antigen-4 show significant antitumor activity and safety in immunotherapy for patients with advanced ESCC.
